8P NXP800 versus cisplatin in ARID1a-mutated ovarian clear cell carcinoma xenograft models

NXP800 (CCT361814) is a Heat Shock Factor (HSF1) pathway inhibitor currently being studied in phase 1 clinical trial (NCT05226507). demonstrated substantial antitumor activity cancer cell lines of different histologies, including ovarian clear and endometrioid carcinoma (OCCC EOC), gastric carcinoma, haematological cancers. Loss function ARID1A was identified as predictive marker for response to OCCC EOC. Here we describe an vivo study versus cisplatin active control cisplatin-resistant cisplatin-sensitive ARID1A-mutated xenografts, supporting the development this indication. In studies were performed by generating subcutaneous tumors Nude (nu/nu) mice using TOV-21G SKOV3 lines. confirmed western blot. Treatment with resulted tumor growth inhibition (TGI) both models. model, baseline volumes vehicle, groups 201.71, 205.66 202.20 mm3, respectively; on Day 28, average 399.84, 236.68 121.47 respectively, representing increases volume 98% vehicle group 15% group, decrease 41% group. 136.2, 138.5 134.7 312.94, 253.71 53.33 130% 80% 60% exhibits notable therapeutic xenografts – condition high unmet medical need limited treatment options sustained tumour regression resistant (SKOV3) sensitive (TOV-21G) Planned 1b expansion cohorts will include patients mutation.